Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,658 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia; Psychosis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia

NCT00001323
View directory record Official record
Conditions
Brain Injury, Dementia, Healthy, Mental Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

NCT00421954
View directory record Official record
Conditions
Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major, Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Adult Study Oxytocin - fMRI

NCT02566356
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Social Cognition, Functional Magnetic Resonance Imaging (fMRI)
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 4 Interventional Results available

Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids

NCT00205712
View directory record Official record
Conditions
Psychoses, Substance-Induced
Interventions
Ketamine, Dexmedetomidine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Not applicable Interventional

Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness

NCT00661869
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Wellness Program
Other
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

NCT05245539
View directory record Official record
Conditions
Blood Pressure, Schizophrenia
Interventions
CVL-231
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
30 Years to 60 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
10
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Long Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Not applicable Interventional

Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings

NCT05030272
View directory record Official record
Conditions
Tobacco Use Disorder, Mental Illness, Recurring Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Persistent Depressive Disorder
Interventions
Quit on the Go App (formerly "Learn to Quit " App), Brief advice, Nicotine patch, Smartphone coaching, Nicotine gum, Nicotine Lozenges
Device · Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Not applicable Interventional

Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings

NCT03286595
View directory record Official record
Conditions
Psychosis, Clinical High Risk for Psychosis
Interventions
Mobi mHealth app
Other
Lead sponsor
University of California, Davis
Other
Eligibility
13 Years to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 11, 2026, 8:47 PM EDT
Terminated No phase listed Observational

Social Cognition in Longstanding Psychosis

NCT01624831
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychosis Not Otherwise Specified (NOS)
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness

NCT00500695
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivational Interviewing, Psychoeducation
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 11, 2026, 8:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ascertaining Diagnosis Classification With Elicited Speech

NCT05601063
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Depressive Disorder, Anxiety Disorders, Personality Disorders, Attention Deficit Hyperactivity Disorder
Interventions
Winterlight Speech Assessment
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 50 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

NCT01683058
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Carson, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 11, 2026, 8:47 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

NCT01844726
View directory record Official record
Conditions
Psychiatric Illness, Healthy
Interventions
GLYX-13, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Not applicable Interventional Results available

Remediation of Auditory Recognition in Schizophrenia With tDCS

NCT02869334
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Active Transcranial direct current stimulation (tDCS), Sham Transcranial direct current stimulation (tDCS), Auditory Remediation, Control computer activities
Device · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Not applicable Interventional Results available

Artemisinin to Reduce The Symptoms of Schizophrenia

NCT00753506
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Artemisinin, Identical looking placebo capsule
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurophysiological Targets for Cognitive Training in Schizophrenia

NCT00923078
View directory record Official record
Conditions
Schizophrenia
Interventions
Auditory Cognitive Training, Visual Cognitive Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia

NCT00149734
View directory record Official record
Conditions
Schizophrenia
Interventions
Ondansetron followed by placebo, Placebo followed by Ondansetron
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

NCT04959032
View directory record Official record
Conditions
Schizophrenia
Interventions
Lumateperone 42 mg, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Little Rock, Arkansas • Bellflower, California • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 2 Interventional

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

NCT00139906
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Phase 4 Interventional Results available

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

NCT00338949
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome X, Insulin Resistance
Interventions
Switch, Control
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 11, 2026, 8:47 PM EDT
Terminated Not applicable Interventional Results available

Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

NCT02739347
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
Active Trans-cranial direct-current stimulation, Sham Trans-cranial direct current stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 11, 2026, 8:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

NCT03077347
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 11, 2026, 8:47 PM EDT
Completed Not applicable Interventional Results available

Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders

NCT01487668
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 11, 2026, 8:47 PM EDT